CANCER:

Ovarian Serous Adenocarcinoma

Related cancers:

‹

Ovarian Cancer (311)

Ovarian Cancer (311)

›

BRAF V600E BRAF V600E	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	encorafenib + binimetinib Sensitive: C1 - Off-label
BRCA2 mutation BRCA2 mutation	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	olaparib + LY2606368 Sensitive: C2 – Inclusion Criteria
KRAS G12D KRAS G12D	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials
KRAS G12A KRAS G12A	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials
KRAS G12V KRAS G12V	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials
Choline elevation Choline elevation	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	pembrolizumab Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	AZD1775 Sensitive: C4 – Case Studies
GOPC-ROS1 fusion GOPC-ROS1 fusion	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	crizotinib Sensitive: C4 – Case Studies
ER Y537N ER Y537N	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	fulvestrant Sensitive: C4 – Case Studies
TMB-H + MSH6 F1088fs TMB-H + MSH6 F1088fs	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies
BRCA2 mutation BRCA2 mutation	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	LY2606368 + LY3023414 Sensitive: D – Preclinical
BRAF L485-P490 deletion BRAF L485-P490 deletion	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	LY3009120 Sensitive: D – Preclinical
PRMT1 underexpression PRMT1 underexpression	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	carboplatin Sensitive: D – Preclinical
PRMT1 underexpression PRMT1 underexpression	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	cisplatin Sensitive: D – Preclinical